Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Feb 10, 2020

Keywords

ClinConnect Summary

This clinical trial is studying systemic sclerosis (SSc), a rare disease that affects the skin and internal organs by causing thickening and hardening of tissues. The goal is to better understand how this disease progresses over time in patients. By following a group of patients for five years, researchers hope to gather important information that can lead to improved treatments.

To participate in this trial, individuals must be over 18 years old and diagnosed with systemic scleroderma based on specific medical criteria. This includes those with early signs of the disease, such as a condition called Raynaud's phenomenon, which causes fingers and toes to change color in response to cold or stress. Participants will need to provide their consent to join the study. It’s important to note that pregnant or breastfeeding women and those under legal protection cannot participate. If eligible, participants can expect regular check-ups and monitoring as part of the study, contributing valuable information to help advance understanding and treatment of this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient over 18 years old
• • Patient with systemic scleroderma according to the ACR/EULAR 2013 criteria, or with a " very early systemic sclerosis " defined by the presence of Raynaud's phenomenon and auto-antibodies in blood sample (ACAN positivity (≥1/160) with anti-Scl70, anti-centromere or anti-ARNPolIII specificity).
• • Person affiliated or benefiting from a social security scheme.
• • Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any review required by the research)
• Exclusion Criteria:
• • Pregnant or breastfeeding woman
• • Patient under guardianship, curatorship or any other legal protection regime